NICE issues draft guidance against Aimovig® (erenumab) for migraines

Written by Sharon Salt (Editor)

Final Appraisal Determination for Aimovig® (erenumab) issued by NICE September 2019: Novartis (Frimley, UK) has announced that Aimovig® (erenumab) has not been recommended by NICE for the treatment of migraines. According to the company, the decision is particularly disappointing as NICE has recognized the clinical effectivness and tolerability of erenumab for chronic migraines and there remains an unmet need for effective and well-tolerated preventive migraine treatments in the UK. At present, Botox® is approved by NICE for chronic migraine, however, the drug may not be suitable for all individuals who are living with migraine as it requires repeated visits to...

To view the full article, please register now for access

It's completely free